MET — Competitive Intelligence Brief

MET (MET) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Endocrinology / Diabetes.

marketed Biguanide AMP-activated protein kinase (AMPK) / mitochondrial complex I Endocrinology / Diabetes Small molecule

Target snapshot

MET (MET) — Ente Ospedaliero Ospedali Galliera. MET is a metformin-based antidiabetic agent that reduces hepatic glucose production and improves insulin sensitivity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MET TARGET	MET	Ente Ospedaliero Ospedali Galliera	marketed	Biguanide	AMP-activated protein kinase (AMPK) / mitochondrial complex I
or Metformin HCl alone	or Metformin HCl alone	Bristol-Myers Squibb	marketed	Biguanide	AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
Glimepiride/metformin fixed combination	Glimepiride/metformin fixed combination	Handok Inc.	marketed	Sulfonylurea/biguanide combination	ATP-sensitive potassium channel (glimepiride); mitochondrial complex I / AMPK pathway (metformin)
Placebo plus metformin	Placebo plus metformin	University Magna Graecia	marketed	Biguanide	AMP-activated protein kinase (AMPK), mitochondrial glycerophosphate dehydrogenase
GLIMEPIRIDE + METFORMIN	GLIMEPIRIDE + METFORMIN	Sanofi	marketed	Sulfonylurea + biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial respiratory chain complex I
Mandated back ground therapy	Mandated back ground therapy	Sanofi	marketed	biguanide
Metformin discontinue	Metformin discontinue	University of Texas Southwestern Medical Center	marketed	Biguanide	AMP-activated protein kinase (AMPK); hepatic glucose production

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

1. AstraZeneca · 4 drugs in this class
2. Merck Sharp & Dohme LLC · 3 drugs in this class
3. University of Texas Southwestern Medical Center · 2 drugs in this class
4. Mount Sinai Hospital, Canada · 2 drugs in this class
5. GlaxoSmithKline · 2 drugs in this class
6. Eli Lilly and Company · 2 drugs in this class
7. University Magna Graecia · 2 drugs in this class
8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class